Vıcıl, SinanErdoğan, Suat2019-07-162019-07-1620151300-0144https://trdizin.gov.tr/publication/paper/detail/TVRjd09UTXdNQT09https://hdl.handle.net/20.500.12483/2425Background/aim: Human alveolar epithelial cells play a critical role in the pathogenesis of lung diseases. Te objective of this study is to determine the contribution of beraprost sodium, a prostaglandin I2 (PGI2) analogue, to infammatory and oxidative events in response to lipopolysaccharide (LPS) in airway epithelial cells. Materials and methods: Human pulmonary alveolar epithelial cells (A549) were pretreated with 10 µM beraprost sodium 30 min before stimulation with 1 µg/mL LPS for 24 h. Te cellular viability assessments were evaluated by quantitative MTT test. Catalase activity and glutathione and lipid peroxidation levels were determined using spectrophotometric techniques. mRNA expression analyses were performed by real-time qRT-PCR. Results: Te endotoxin induced a dose-dependent increase in proliferation of the cells, which was suppressed by the beraprost sodium treatment. LPS increased the expressions of TNF-α and IL-1β genes by 8- and 2.5-fold, respectively. It also induced lipid peroxidation and depleted cellular antioxidant capacity. Pretreatments of the cells with beraprost sodium signifcantly reversed the infammation and suppressed oxidative stress. Conclusion: Tese fndings suggest that beraprost sodium will provide a pivotal molecular basis for the design of new therapeutic strategies to cure endotoxin-induced lung injury, although additional comprehensive studies are still required.Background/aim: Human alveolar epithelial cells play a critical role in the pathogenesis of lung diseases. Te objective of this study is to determine the contribution of beraprost sodium, a prostaglandin I2 (PGI2) analogue, to infammatory and oxidative events in response to lipopolysaccharide (LPS) in airway epithelial cells. Materials and methods: Human pulmonary alveolar epithelial cells (A549) were pretreated with 10 µM beraprost sodium 30 min before stimulation with 1 µg/mL LPS for 24 h. Te cellular viability assessments were evaluated by quantitative MTT test. Catalase activity and glutathione and lipid peroxidation levels were determined using spectrophotometric techniques. mRNA expression analyses were performed by real-time qRT-PCR. Results: Te endotoxin induced a dose-dependent increase in proliferation of the cells, which was suppressed by the beraprost sodium treatment. LPS increased the expressions of TNF-α and IL-1β genes by 8- and 2.5-fold, respectively. It also induced lipid peroxidation and depleted cellular antioxidant capacity. Pretreatments of the cells with beraprost sodium signifcantly reversed the infammation and suppressed oxidative stress. Conclusion: Tese fndings suggest that beraprost sodium will provide a pivotal molecular basis for the design of new therapeutic strategies to cure endotoxin-induced lung injury, although additional comprehensive studies are still required.eninfo:eu-repo/semantics/openAccessCerrahiBeraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cellsArticle452284290260841162-s2.0-84926358686Q1WOS:000352482000005Q4